81 results about "Cell signaling pathways" patented technology

This invention is directed to a method for preparation of a biological sample for measurement of protein epitopes that allows for the preservation of intracellular protein epitopes and detection of signal transduction pathways based on the ability to capture transient activation states of the epitopes. The method provided by the invention allows for the rapid fixation of biological samples containing red blood cells, to ensure that epitopes of signal transduction molecules and other intracellular protein epitopes are preserved in the active state. The method of the invention further allows for lysis of red blood cells, thereby making it a useful method for cytometric analysis of biological samples, including, for example, whole blood, bone marrow aspirates, peritoneal fluids, and other red blood cell containing samples. The invention also provides a method to recover or “unmask” epitopes on intracellular antigens that have been made inaccessible by the cross linking fixative necessary to fix the sample. Significantly, the methods of the invention allow preservation and analysis of phospho-epitope levels in biological samples taken directly from patients to determine disease-specific characteristics.

The invention belongs to the technical field of culture media, and particularly relates to a reprogramming medium for a human induced pluripotent stem cell (hiPSC). The reprogramming medium comprisesan adult cell culture medium for culturing a human somatic cell and a cell signaling pathway inhibitor added to the adult cell culture medium; and the cell signaling pathway inhibitor is any one of ora combination containing more of a glycogen synthase kinase 3 inhibitor, a mitogen-activated protein kinase kinase inhibitor and a transforming growth factor beta inhibitor. The reprogramming mediumis obtained through adding one or more small-molecular compounds to adult cell culture medium, is used for induced reprogramming culture or induced differentiation culture, is a non-trophoblastic animal origin-free medium, greatly improves the speed and the efficiency of reprogramming of the human somatic cell into the human pluripotent stem cell, and especially can efficiently reprogram the humansomatic cell into the hiPSC for expressing specific markers.

There is provided a cell line that is prepared by transforming HEK293 cell with a human Kir2.1 gene using a retrovirus expression system, wherein the HEK293 expresses a stable α1G T-type calcium channel. The cell line responds sensitively to KCl and forms an appropriate level of the membrane voltage so that the cell signaling pathway may be investigated by the molecular biological and biochemical studies.

The present invention discloses an anti-tumor polypeptide and an application thereof in preparing anti-tumor drugs. Aiming at a molecular structure, a ligand binding mode and amino acid sequence characteristics of a NRP-1 transmembrane region, and the transmembrane region capable of specifically binding the human source NRP-1 molecular structure and binding ligands is designed to block binding ofNRP-1 with a variety of the ligands of VEGF, EGF, and HGF, thereby blocking the anti-tumor polypeptide drugs of downstream cellular signaling pathways. The anti-tumor polypeptide binds to the NRP-1 transmembrane region monomer competitively, interferes dimerization of NRP-1, inhibits the binding of the NRP-1 to the ligands, thus inhibits activation of various tumor cell signaling pathways, and achieves purposes of inhibiting tumor cell proliferation, migration and infiltration, and promoting apoptosis. The provided anti-tumor polypeptide provides a new technical means for treatment of tumors.

The invention discloses an anti-tumor polypeptide with double effects and an application thereof. The anti-tumor polypeptide with double effects has an amino acid sequence shown as SEQ ID NO.4. The polypeptide provided by the invention can specifically target NRP-1 molecules expressed on endothelial cells and tumor cells, improve the permeability of vascular endothelial cells and increase the permeability of tumor tissues, thereby improving the capacity of a drug penetrating through a vascular barrier and permeating into the tumor tissues. Meanwhile, proliferation of cancer cells can be inhibited and apoptosis of the cancer cells can be promoted by blocking a downstream cell signal path regulated and controlled by NRP-1. The polypeptide disclosed by the invention can be used for treating various solid tumors including pancreatic cancer, and can improve the effect of treating malignant tumors by using drugs, especially using a monoclonal antibody targeted drug.